Fluck R J, Raine A E
Department of Nephrology, St Bartholomew's Hospital, London.
Br Heart J. 1994 Sep;72(3 Suppl):S46-51. doi: 10.1136/hrt.72.3_suppl.s46.
In non-diabetic renal disease ACE inhibitors have brought both benefit and problems. On the one hand, they are undoubtedly effective antihypertensive agents and data suggest that they may have a beneficial role in the prevention of progression of renal disease, although further placebo controlled double blind trials of adequate duration are required. On the other hand, their widespread use in elderly patients and those with generalised atherosclerosis has increased the risk of acute renal failure when occult renovascular disease is present. Awareness among physicians of the high rate of renovascular disease in populations at risk is to be encouraged.
在非糖尿病肾病中，血管紧张素转换酶抑制剂既带来了益处，也引发了问题。一方面，它们无疑是有效的抗高血压药物，数据表明它们可能在预防肾病进展方面发挥有益作用，不过仍需要进行足够时长的进一步安慰剂对照双盲试验。另一方面，它们在老年患者和患有全身性动脉粥样硬化的患者中广泛使用，增加了存在隐匿性肾血管疾病时发生急性肾衰竭的风险。应鼓励医生提高对高危人群中肾血管疾病高发病率的认识。
